In summary, we demonstrated that the use of an insulin sensitizer, in this case OFS, in conjunction with an immune modulatory therapy (i.e. aCD3), is a viable paradigm to induce diabetes remission in early established diabetes. This evidence concerns the gene INS and diabetes mellitus.